Liberate Bio’s investigational CAR-M cell therapy LIB820 may help successfully eliminate disease-driving B-cells in autoimmune diseases such as multiple sclerosis (MS) without causing severe side effects, according to new preclinical data. The therapy is designed to genetically engineer two types of immune cells — monocytes and macrophages — within the patient’s body (in vivo) to specifically […]

The post Latest preclinical data support promise of CAR-M cell therapy LIB820 appeared first on Multiple Sclerosis News Today.

Source: multiplesclerosisnewstoday.com